Combivir Users Warned About Label-Switching Reports
GlaxoSmithKline has received four reports of label switching on bottles of pills which should have contained Combivir, but actually contained Ziagen. Manufacturers are warning users of the medication Combivir to inspect their bottles and the tablets themselves prior to use.
While both medications are used to treat HIV infection (and are combined in Trizivir), they have very different side effects. Ziagen side effects can include hypersensitivity, which in some instances can be fatal.
Consumers with questions may call GlaxoSmithKline at (888) 825-5249.
This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.